MAVS Antibody (E-3): sc-166583

MAVS Antibody (E-3) is a mouse monoclonal IgG2a kappa light chain antibody that detects MAVS protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). MAVS (E-3) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. MAVS, or mitochondrial antiviral-signaling protein, is a crucial 540 amino acid protein that features one CARD domain and several transmembrane domains, localizing primarily to the outer mitochondrial membrane. MAVS plays a vital role in the immune response by functioning downstream of RIG-I, a protein that detects double-stranded viral RNA, thereby initiating a signaling cascade that leads to the production of antiviral cytokines. MAVS functioning is essential for an effective immune response against viral infections, as MAVS helps to activate pathways that not only promote the expression of these cytokines but also protect cells from viral-induced apoptosis. MAVS can be inactivated through cleavage by a protease complex that degrades CARD and transmembrane domains, which prevents interaction with other critical proteins in the immune signaling pathway. MAVS is subject to alternative splicing, resulting in the expression of three distinct isoforms, which may have different regulatory roles in immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MAVS Antibody (E-3) References:

1. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.  |  Li, XD., et al. 2005. Proc Natl Acad Sci U S A. 102: 17717-22. PMID: 16301520
2. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.  |  Loo, YM., et al. 2006. Proc Natl Acad Sci U S A. 103: 6001-6. PMID: 16585524
3. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms.  |  Cheng, G., et al. 2006. Proc Natl Acad Sci U S A. 103: 8499-504. PMID: 16707574
4. Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage.  |  Lin, R., et al. 2006. J Virol. 80: 6072-83. PMID: 16731946
5. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif.  |  Saha, SK., et al. 2006. EMBO J. 25: 3257-63. PMID: 16858409
6. Legionella pneumophila induces IFNbeta in lung epithelial cells via IPS-1 and IRF3, which also control bacterial replication.  |  Opitz, B., et al. 2006. J Biol Chem. 281: 36173-9. PMID: 16984921
7. GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS.  |  Chen, Z., et al. 2007. J Virol. 81: 964-76. PMID: 17093192
8. Activation of innate immune defense mechanisms by signaling through RIG-I/IPS-1 in intestinal epithelial cells.  |  Hirata, Y., et al. 2007. J Immunol. 179: 5425-32. PMID: 17911629
9. Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling.  |  Lad, SP., et al. 2008. Mol Immunol. 45: 2277-87. PMID: 18207245
10. Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS.  |  Zhang, W., et al. 2019. Cell. 178: 176-189.e15. PMID: 31155231
11. MAVS integrates glucose metabolism and RIG-I-like receptor signaling.  |  He, QQ., et al. 2023. Nat Commun. 14: 5343. PMID: 37660168
12. CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity.  |  Zhang, G., et al. 2023. Mol Cell. 83: 4370-4385.e9. PMID: 38016475

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-MAVS Antibody (E-3) has 111 citations in a variety of scientific publications.

Primary antibodies like Anti-MAVS Antibody (E-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

MAVS Antibody (E-3) Specifications

Alternate Product Name: MAVS

Product Clone Name: E-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 1-135

Epitope Target: MAVS

Epitope Species: human

Product Reactivity/Detection: MAVS

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 111 citations in various scientific publications

Available Conjugates/Forms for MAVS Antibody (E-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred MAVS antibody is MAVS Antibody (E-6): sc-365334.